Table 1.
Baseline characteristics of SPRINT participants stratified by combined LVH and cardiac biomarker categories
| Characteristica | LVH− biomarker− (n=4,361) | LVH− biomarker+ (n=3,761) | LVH+ biomarker− (n=249) | LVH+ biomarker+ (n=449) |
|---|---|---|---|---|
| Intensive BP arm | 2168 (50%) | 1918 (51%) | 121 (49%) | 211 (47%) |
| Age, years | 64 (8) | 72 (9) | 64 (8) | 70 (10) |
| Female | 1471 (34%) | 1346 (36%) | 169 (68%) | 260 (58%) |
| African Americanb | 1493 (34%) | 877 (23%) | 146 (59%) | 210 (47%) |
| Hispanicb | 581 (13%) | 290 (8%) | 32 (13%) | 41 (9%) |
| Current smoker | 670 (15%) | 377 (10%) | 43 (17%) | 57 (13%) |
| Prevalent CVD | 568 (13%) | 994 (26%) | 41 (16%) | 147 (33%) |
| Prevalent heart failureb | 67 (2%) | 187 (5%) | 5 (2%) | 41 (9%) |
| Systolic BP | ||||
| ≤132 mmHg | 573 (13%) | 448 (12%) | 20 (8%) | 28 (6%) |
| >132 mmHg to <145 mmHg | 1864 (43%) | 1579 (42%) | 72 (29%) | 147 (33%) |
| ≥145 mmHg | 1924 (44%) | 1734 (46%) | 157 (63%) | 274 (61%) |
| Diastolic BP | ||||
| ≤70 mmHg | 471 (11%) | 1130 (30%) | 25 (10%) | 122 (27%) |
| >70 mmHg to <80 mmHg | 1148 (26%) | 1090 (29%) | 61 (25%) | 120 (27%) |
| ≥80 mmHg | 2742 (63%) | 1541 (41%) | 163 (65%) | 207 (46%) |
| Total med burden ≥5 | 2070 (48%) | 2478 (66%) | 111 (45%) | 278 (62%) |
| Number of BP meds | 2 (1, 2) | 2 (1, 3) | 2 (1, 3) | 2 (2, 3) |
| BMI, kg/m2 | 30.2 (5.5) | 29.3 (5.8) | 30.4 (6.0) | 29.3 (5.7) |
| eGFR, mL/min/1.73m2 | 77 (19) | 65 (20) | 81 (20) | 65 (21) |
| Urine ACR, mg/g | 8 (5, 15) | 12 (7, 32) | 9 (6, 21) | 16 (8, 45) |
| hs-cTnT, ng/L | 7.3 (3, 9.7) | 14.4 (9.2, 19.6) | 7.1 (3, 9.9) | 15.3 (9.9, 21.1) |
| NT-proBNP, pg/mL | 44 (22, 74) | 198 (131, 352) | 55 (29, 86) | 308 (168, 569) |
| Cornell voltage index, μV | 1422 (1071, 1782) | 1409 (1043, 1797) | 2800 (2373, 3073) | 2883 (2465, 3259) |
| Sokolow-Lyon, μV | 2032 (1610, 2508) | 2034 (1570, 2580) | 2444 (2063, 3088) | 2661 (2056, 3420.5) |
Data displayed as N (%), mean (SD), or median (IQR).
LVH+ defined as Cornell voltage index on baseline ECG ≥2,200 microvolt (μV) in women and ≥2,800 μV in men. Biomarker+ defined as baseline hscTnT ≥ 14 ng/L or NTproBNP ≥ 125 pg/mL.
Abbreviations: ACR, albumin-to-creatinine ratio; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; hs-cTnT, high-sensitivity cardiac troponin T; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SPRINT, Systolic Blood Pressure Intervention Trial.
All P values testing for differences in baseline characteristics across combined LVH and biomarker groups were <0.001 except for intensive BP arm (P =0.33).
Race, ethnicity, and history of heart failure were self-reported.